文献速递重症综合管理与镇静镇痛心脑血管急症创伤与烧伤

创伤性脑损伤中限制性 vs 开放性输血策略:TRAIN试验的二次分析

Restrictive vs Liberal Transfusion Strategy in Traumatic Brain Injury: A Secondary Analysis of the TRAIN Trial.
PubMed 文献 · JAMA Netw Open · 2026-09-01
一句话结论TBI贫血患者开放性输血(Hb<9 g/dL)较限制性(Hb<7 g/dL)与180天不良神经结局风险更低相关(RR 0.86),但脆弱指数仅1,需谨慎解读。

这是TRAIN多中心RCT的预设二次分析,纳入72个ICU、22个国家共486例TBI患者(475例进入主要结局分析),比较开放性(Hb<9 g/dL)与限制性(Hb<7 g/dL)红细胞输注策略。28天死亡率、感染、脑缺血等严重不良事件无显著差异。作者结论为开放性策略与更低不良神经结局风险相关,但因估计不确定性需谨慎解读。

适用人群与场景

  • 原文未提及具体纳入/排除标准细节(如Hb入组界值、GCS范围、颅外损伤情况等)。

诊断标准与关键阈值

  • 输血启动阈值:开放性策略为Hb<9 g/dL(原文注明换算为g/L需乘以10.0);限制性策略为Hb<7 g/dL;策略最长执行28天。
  • 主要结局不良神经功能采用Glasgow结局扩展量表(GOSE)评分1-5分(总分1-8分,高分示结局更佳),评估时点为180天。

处置流程与药物剂量

  • 第一步:对TBI合并贫血患者,按随机分组策略决定红细胞输注时机——开放性组Hb<9 g/dL时输注,限制性组Hb<7 g/dL时输注,策略最长持续28天。
  • 第二步:原文未提及具体输注剂量、单位、频次或目标Hb值,仅报告开放性组共输注534次RBCT、限制性组246次RBCT。
  • 第三步:原文未提及除Hb阈值外的其他输血指征或辅助措施。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的红旗征及对应处理。

研究设计与关键结果

  • 研究类型:TRAIN多中心RCT的预设二次分析;样本量486例TBI患者(475例进入主要结局分析),来自72个ICU、22个国家;开放性组236例、限制性组239例。
  • 人群特征:平均(SD)年龄46.8(17.6)岁,男性347例(71.4%);两组基线特征相似。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(RCT)的预设二次分析(TRAIN试验,NCT02968654)。
  • 局限:原文指出主要结局估计存在固有不确定性(脆弱指数=1),结论应谨慎解读;二次分析设计本身亦限制因果推断强度。

对床旁实践的改变

  • 对TBI合并贫血的ICU患者,该二次分析提示开放性输血阈值(Hb<9 g/dL)可能较限制性阈值(Hb<7 g/dL)与更低的180天不良神经结局风险相关,但证据脆弱(脆弱指数=1),不建议单独据此改变输血策略。
  • 原文未提及适用与不适用人群的具体排除标准,亦未提及常见陷阱的具体内容。

指南或共识出处

  • TRAIN试验(Transfusion Strategies in Acute Brain Injured Patients,ClinicalTrials.gov NCT02968654)的预设二次分析,发表于JAMA Network Open。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Anemia is a prevalent condition among patients with traumatic brain injury (TBI); however, the optimal hemoglobin (Hb) threshold to initiate red blood cell transfusion (RBCT) is not well defined.

OBJECTIVE: To assess which of 2 different Hb thresholds for guiding RBCT in patients with anemia and TBI is associated with a more favorable neurological outcome.

DESIGN, SETTING, AND PARTICIPANTS: This was a preplanned secondary analysis of the Transfusion Strategies in Acute Brain Injured Patients multicentric randomized clinical trial, conducted in 72 intensive care units across 22 countries between September 1, 2017, and December 31, 2022. Follow-up was completed June 30, 2023. Only patients with TBI were included in the present analysis, conducted from February to May 2025.

INTERVENTIONS: Liberal (transfusion at Hb <9 g/dL [to convert to g/L, multiply by 10.0]) vs restrictive (transfusion at Hb <7 g/dL) RBCT strategy over a maximum of 28 days.

MAIN OUTCOME AND MEASURES: The primary outcome was the occurrence of unfavorable neurological outcome, defined as a Glasgow Outcome Scale Extended score of 1 to 5 (overall range, 1-8, with higher scores indicating more favorable outcome) at 180 days. In addition, 14 prespecified serious adverse events, including infection and cerebral ischemia, were assessed. Data were analyzed using both the intention-to-treat and per-protocol principles.

RESULTS: Of 486 patients who presented with TBI (mean [SD] age, 46.8 [17.6] years; 347 [71.4%] male), 475 were included in the primary outcome analysis: 236 were randomized to the liberal transfusion strategy group and 239 to the restrictive transfusion strategy group. Both groups had similar baseline characteristics. In total, 534 RBCTs were administered in the liberal transfusion strategy group, compared with 246 RBCTs in the restrictive group. At 180 days after randomization, 138 patients (58.5%) in the liberal group had unfavorable neurological outcome compared with 161 patients (67.4%) in the restrictive group (relative risk [RR], 0.86 [95% CI, 0.75-1.00]; P = .047; fragility index = 1). There were no significant differences in the occurrence of secondary outcomes (eg, 28-day mortality: 42 of 240 [17.5%] vs 51 of 244 [20.9%]; RR, 0.84 [95% CI, 0.58-1.21]; P = .34) or serious adverse events (eg, RR, 1.13 [95% CI, 0.88-1.43]; P = .34 for infection and RR, 0.87 [95% CI, 0.40-1.90]; P = .72 for cerebral ischemia). After adjustment for several confounders, being randomized to the liberal group was associated with a lower observed probability of unfavorable neurological outcome (odds ratio, 0.60 [95% CI, 0.38-0.94]; P = .03).

CONCLUSIONS AND RELEVANCE: In this secondary analysis of a multicenter randomized clinical trial, a liberal RBCT strategy was associated with a lower risk than a restrictive RBCT strategy of unfavorable neurological outcome at 180 days among patients with TBI. These findings should be interpreted with caution in light of the inherent uncertainty of the estimate.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02968654.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Zernini IS, Faso C, Rynkowski CB, et al. Restrictive vs Liberal Transfusion Strategy in Traumatic Brain Injury: A Secondary Analysis of the TRAIN Trial. JAMA Netw Open. 2026. PMID: 42709438. doi:10.1001/jamanetworkopen.2026.32555

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。